The LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Kurakula, Kondababu ^a   Vos, Mariska ^a   Rubio, Iker Otermin ^a   Marinković, Goran ^a   Buettner, Reinhard ^b   Heukamp, Lukas C ^b   Stap, Jan ^a   De Waard, Vivian ^a   Van Tiel, Claudia M ^a   De Vries, Carlie J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; FOUR AND HALF LIM DOMAIN PROTEIN 2; KI 67 ANTIGEN; LIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; FHL2 PROTEIN, MOUSE; LIM HOMEODOMAIN PROTEIN; MUSCLE PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; MIGRATION INHIBITION; MITOSIS INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; CAROTID ARTERY; CELL MOTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; CAROTID ARTERIES; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; LIM-HOMEODOMAIN PROTEINS; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84899677136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094931     Document Type: Article

References (35)

1. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767-801. doi:10.1152/physrev.000412003
2. Doran AC, Meller N, McNamara CA (2008) Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28: 812-819. doi:10.1161/ATVBAHA.107.159327
3. Ross R (1995) Cell biology of atherosclerosis. Annu Rev Physiol 57: 791-804. doi:10.1146/annurev.ph.57.030195.004043
4. Ross R (1993) The Pathogenesis of Atherosclerosis - A Perspective for the 1990S. Nature 362: 801-809. doi:10.1038/362801a0
5. Weintraub WS (2007) The pathophysiology and burden of restenosis. Am J Cardiol 100: 3K-9K. doi:10.1016/j.amjcard.2007.06.002
6. Mitra AK, Agrawal DK (2006) In stent restenosis: bane of the stent era. J Clin Pathol 59: 232-239. doi:10.1136/jcp.2005.025742
7. Chandrasekar B, Tanguay JF (2000) Platelets and restenosis. J Am Coll Cardiol 35: 555-562. doi:10.1016/S0735-1097(99)00596-3
8. Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, et al. (1997) Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95: 1998-2002. doi:10.1161/01.CIR.95.8.1998
9. Johannessen M, Moller S, Hansen T, Moens U, Van GM (2006) The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 63: 268-284. doi:10.1007/s00018-005-5438-z
10. Philippar U, Schratt G, Dieterich C, Muller JM, Galgoczy P, et al. (2004) The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol Cell 16: 867-880. doi:10.1016/j.molcel.2004.11.039
11. Kurakula K, van der Wal E, Geerts D, van Tiel CM, de Vries CJ (2011) FHL2 protein is a novel co-repressor of nuclear receptor Nur77. J Biol Chem 286: 44336-44343. doi:10.1074/jbc.M111.308999
12. Neuman NA, Ma S, Schnitzler GR, Zhu Y, Lagna G, et al. (2009) The four-anda- half LIM domain protein 2 regulates vascular smooth muscle phenotype and vascular tone. J Biol Chem 284: 13202-13212. doi:10.1074/jbc.M900282200
13. Purcell NH, Darwis D, Bueno OF, Muller JM, Schule R, et al. (2004) Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 24: 1081-1095. doi:10.1128/MCB.24.3.1081-1095.2004
14. Paul C, Lacroix M, Iankova I, Julien E, Schafer BW, et al. (2006) The LIM-only protein FHL2 is a negative regulator of E4F1. Oncogene 25: 5475-5484. doi:10.1038/sj.onc.1209567
15. Kong Y, Shelton JM, Rothermel B, Li X, Richardson JA, et al. (2001) Cardiacspecific LIM protein FHL2 modifies the hypertrophic response to betaadrenergic stimulation. Circulation 103: 2731-2738. doi:10.1161/ 01.CIR.103.22.2731
16. Hinson JS, Medlin MD, Taylor JM, Mack CP (2008) Regulation of myocardin factor protein stability by the LIM-only protein FHL2. Am J Physiol Heart Circ Physiol 295: H1067-H1075. doi:10.1152/ajpheart.91421.2007
17. Chu PH, Yeh HI, Wu HH, Hong RC, Shiu TF, et al. (2010) Deletion of the FHL2 gene attenuates the formation of atherosclerotic lesions after a cholesterolenriched diet. Life Sci 86: 365-371. doi:10.1016/j.lfs.2010.01.007
18. Kumar A, Lindner V (1997) Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17: 2238-2244. doi:10.1161/01.ATV.17.10.2238
19. Bonta PI, Matlung HL, Vos M, Peters SL, Pannekoek H, et al. (2010) Nuclear receptor Nur77 inhibits vascular outward remodelling and reduces macrophage accumulation and matrix metalloproteinase levels. Cardiovasc Res 87: 561-568. doi:10.1093/cvr/cvq064
20. Geisterfer AA, Peach MJ, Owens GK (1988) Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62: 749-756. doi:10.1161/01.RES.62.4.749
21. Goncharova EA, Goncharov DA, Krymskaya VP (2006) Assays for in vitro monitoring of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cell migration. Nat Protoc 1: 2933-2939. doi:10.1038/nprot.2006.434
22. Molenaar JJ, Ebus ME, Koster J, Santo E, Geerts D, et al. (2010) Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 29: 2739-2745. doi:10.1038/onc.2010.21
23. Labalette C, Nouet Y, Sobczak-Thepot J, Armengol C, Levillayer F, et al. (2008) The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation. J Biol Chem 283: 15201-15208. doi:10.1074/jbc.M800708200
24. Konig K, Diehl L, Rommerscheidt-Fuss U, Golletz C, Quast T, et al. (2010) Four-and-a-Half LIM Domain Protein 2 Is a Novel Regulator of Sphingosine 1- Phosphate Receptor 1 in CCL19-Induced Dendritic Cell Migration. J Immunol 185: 1466-1475. doi:10.4049/jimmunol.0903449
25. Wixler V, Hirner S, Muller JM, Gullotti L, Will C, et al. (2007) Deficiency in the LIM-only protein Fhl2 impairs skin wound healing. J Cell Biol 177: 163-172. doi:10.1083/jcb.200606043
26. Braun-Dullaeus RC, Mann MJ, Dzau VJ (1998) Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98: 82-89. doi:10.1161/01.CIR.98.1.82
27. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM (1993) Proliferative Activity in Peripheral and Coronary Atherosclerotic Plaque Among Patients Undergoing Percutaneous Revascularization. J Clin Invest 91: 1469-1480. doi:10.1172/JCI116352
28. Hayashi H, Nakagami H, Takami Y, Koriyama H, Mori M, et al. (2009) FHL-2 Suppresses VEGF-Induced Phosphatidylinositol 3-Kinase/Akt Activation via InteractionWith Sphingosine Kinase-1. Arterioscler Thromb Vasc Biol 29: 909- U331. doi:10.1161/ATVBAHA.108.178541
29. Huang PH, Chen CY, Lin CP, Wang CH, Tsai HY, et al. (2013) Deletion of FHL2 gene impaired ischemia-induced blood flow recovery by modulating circulating proangiogenic cells. Arterioscler Thromb Vasc Biol 33: 709-717. doi:10.1161/ATVBAHA.112.300318
30. Ng CF, Ng PKS, Lui VWY, Li JL, Chan JYW, et al. (2011) FHL2 exhibits antiproliferative and anti-apoptotic activities in liver cancer cells. Cancer Lett 304: 97-106. doi:10.1016/j.canlet.2011.02.001
31. Amann T, Egle Y, Bosserhoff AK, Hellerbrand C (2010) FHL2 suppresses growth and differentiation of the colon cancer cell line HT-29. Oncol Rep 23: 1669-1674. doi:10.3892/or-00000810
32. Gerthoffer WT (2007) Mechanisms of vascular smooth muscle cell migration. Circ Res 100: 607-621. doi:10.1161/01.RES.0000258492.96097.47
33. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, et al. (2003) Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 23: 795-801. doi:10.1161/01.ATV.0000066132.32063.F2
34. Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, et al. (2001) Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in ballooninjured rat artery. Circ Res 88: 1120-6. doi:10.1161/hh1101.091267
35. Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC (1998) Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg 27: 117-125. doi:http://dx.doi.org/10.1016/S0741-5214(98)70298-8